Central Bank & Trust’s Guardant Health GH Stock Holding History

Central Bank & Trust’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19	Closed	-$445	–	369
2023 Q1	$445	Buy	+19	New	+$543	﹤0.01%	411

Other funds holding GH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Central Bank & Trust's GH Position: Q2 2023 in Review

Central Bank & Trust sold out of Guardant Health (GH) in Q2 2023, closing a stake of 19 shares — an estimated $445 sold.

Central Bank & Trust first reported a position in GH in Q1 2023 and held it in 1 quarter. The position peaked at $445 in Q1 2023. 299 funds tracked by Wall St. Rank hold GH as of Q2 2023.

Central Bank & Trust reported no remaining Guardant Health position as of Q2 2023 after selling out during the quarter.
Central Bank & Trust sold 19 Guardant Health shares in Q2 2023, an estimated $445.
Central Bank & Trust first reported a position in Guardant Health in Q1 2023 and held it in 1 quarter.
Central Bank & Trust's Guardant Health position peaked at $445 in Q1 2023.
299 funds tracked by Wall St. Rank held Guardant Health as of Q2 2023.

Based on Central Bank & Trust's 13F filing for Q2 2023, filed 13 Jul 2023.